{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:28:55Z","timestamp":1707524935799},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,9]]},"DOI":"10.7759\/cureus.35922","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T09:52:00Z","timestamp":1678355520000},"source":"Crossref","is-referenced-by-count":1,"title":["Incidence and Risk Factors of Infections Among Diffuse Large B-cell Lymphoma and Classical Hodgkin\u2019s Lymphoma Patients in a Tertiary Care Center in Saudi Arabia: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Rakan H","family":"Alelyani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali H","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thamer A","family":"Almughamisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman M","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulaziz N","family":"Kadasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir M","family":"Alrajhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah K","family":"Alburayk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed S","family":"Barefah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman O","family":"Radhwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah T","family":"Almohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salem M","family":"Bahashawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem M","family":"AlAhwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Cancer incidence report. Saudi Arabia 2015. (2015). Accessed. January 8, 2023: https:\/\/nhic.gov.sa\/eServices\/Documents\/E%20SCR%20final%206%20NOV.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth JD","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris HA 3rd, et al.. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002, 20:4261-7. 10.1200\/JCO.2002.08.674","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5827","article-title":"Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead","volume":"33","author":"Minard-Colin V","year":"2015","unstructured":"Minard-Colin V, Brugi\u00e8res L, Reiter A, et al.. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015, 33:2963-74. 10.1200\/JCO.2014.59.5827","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann W","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al.. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005, 106:3725-32. 10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/nm1096-1104","article-title":"The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response","volume":"2","author":"Rehermann B","year":"1996","unstructured":"Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996, 2:1104-8. 10.1038\/nm1096-1104","journal-title":"Nat Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/0018578717741394","article-title":"Detection of the incidence of HBV, HCV infection and febrile neutropenia associated with CHOP with or without rituximab in diffuse large B-cell lymphoma-treated patients","volume":"53","author":"Ali K","year":"2018","unstructured":"Ali K, Sial AA, Baig MT, Baig N, Ansari SH, Shamsi TS. Detection of the incidence of HBV, HCV infection and febrile neutropenia associated with CHOP with or without rituximab in diffuse large B-cell lymphoma-treated patients. Hosp Pharm. 2018, 53:194-7. 10.1177\/0018578717741394","journal-title":"Hosp Pharm"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11827","article-title":"Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma","volume":"98","author":"Lyman GH","year":"2003","unstructured":"Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003, 98:2402-9. 10.1002\/cncr.11827","journal-title":"Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-011-1306-6","article-title":"Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma","volume":"20","author":"Pettengell R","year":"2012","unstructured":"Pettengell R, Johnsen HE, Lugtenburg PJ, et al.. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 2012, 20:647-52. 10.1007\/s00520-011-1306-6","journal-title":"Support Care Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier B","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al.. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010, 116:2040-5. 10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh M","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, et al.. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008, 9:105-16. 10.1016\/S1470-2045(08)70002-0","journal-title":"Lancet Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.0765","article-title":"Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study","volume":"35","author":"Jakobsen LH","year":"2017","unstructured":"Jakobsen LH, B\u00f8gsted M, Brown PN, et al.. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study. J Clin Oncol. 2017, 35:778-84. 10.1200\/JCO.2016.70.0765","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00614-8","article-title":"Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark","volume":"12","author":"Jakobsen LH","year":"2022","unstructured":"Jakobsen LH, \u00d8vlisen AK, Severinsen MT, et al.. Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark. Blood Cancer J. 2022, 12:16. 10.1038\/s41408-022-00614-8","journal-title":"Blood Cancer J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer MJ","year":"2014","unstructured":"Maurer MJ, Ghesqui\u00e8res H, Jais JP, et al.. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014, 32:1066-73. 10.1200\/JCO.2013.51.5866","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007941.pub3","article-title":"Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma","volume":"5","author":"Skoetz N","year":"2017","unstructured":"Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017, 5:CD007941. 10.1002\/14651858.CD007941.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: the past, present, and future","volume":"5","author":"Evens AM","year":"2008","unstructured":"Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol. 2008, 5:543-56. 10.1038\/ncponc1186","journal-title":"Nat Clin Pract Oncol"},{"key":"ref16","unstructured":"Survival rates and factors that affect prognosis (outlook) for non-Hodgkin lymphoma. (2022). Accessed. January 8, 2023: https:\/\/www.cancer.org\/cancer\/non-hodgkin-lymphoma\/detection-diagnosis-staging\/factors-prognosis.html."},{"key":"ref17","unstructured":"Survival rates for Hodgkin lymphoma. (2022). Accessed. January 8, 2023: https:\/\/www.cancer.org\/cancer\/hodgkin-lymphoma\/detection-diagnosis-staging\/survival-rates.html."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.24875\/RIC.19002982","article-title":"Infectious complications as a predictor of mortality in patients with non-Hodgkin lymphoma receiving rituximab-containing chemotherapy","volume":"71","author":"Meza-Meneses P","year":"2019","unstructured":"Meza-Meneses P, Cornejo-Ju\u00e1rez P, Vilar-Compte D, Volkow-Fern\u00e1ndez P. Infectious complications as a predictor of mortality in patients with non-Hodgkin lymphoma receiving rituximab-containing chemotherapy. Rev Invest Clin. 2019, 71:275-82. 10.24875\/RIC.19002982","journal-title":"Rev Invest Clin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney DG","year":"1997","unstructured":"Maloney DG, Grillo-Lopez AJ, White CA, et al.. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997, 90:2188-95. 10.1182\/blood.V90.6.2188","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.10399","article-title":"Infections in patients with lymphoma: an analysis of incidence, relationship and risk factors","volume":"12","author":"Y\u0131ld\u0131z A","year":"2018","unstructured":"Y\u0131ld\u0131z A, Albayrak M, Pala \u00c7, et al.. Infections in patients with lymphoma: an analysis of incidence, relationship and risk factors. J Infect Dev Ctries. 2018, 12:741-7. 10.3855\/jidc.10399","journal-title":"J Infect Dev Ctries"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-3280","article-title":"Incidence and risk factors of pneumonia in diffuse large B-cell lymphoma patients receiving first line R-CHOP\/R-CHOP-like immunochemotherapy: a retrospective study of 287 patients in single center","volume":"10","author":"Wang J","year":"2021","unstructured":"Wang J, Liu F, Tang X. Incidence and risk factors of pneumonia in diffuse large B-cell lymphoma patients receiving first line R-CHOP\/R-CHOP-like immunochemotherapy: a retrospective study of 287 patients in single center. Ann Palliat Med. 2021, 10:11931-8. 10.21037\/apm-21-3280","journal-title":"Ann Palliat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2021","unstructured":"NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021, 398:957-80. 10.1016\/S0140-6736(21)01330-1","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.01294","article-title":"Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach","volume":"9","author":"Madeddu C","year":"2018","unstructured":"Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macci\u00f2 A. Pathogenesis and treatment options of cancer related anemia: perspective for a targeted mechanism-based approach. Front Physiol. 2018, 9:1294. 10.3389\/fphys.2018.01294","journal-title":"Front Physiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101696","article-title":"Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropenia","volume":"9","author":"Ammann RA","year":"2014","unstructured":"Ammann RA, Niggli FK, Leibundgut K, Teuffel O, Bodmer N. Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropenia. PLoS One. 2014, 9:e101696. 10.1371\/journal.pone.0101696","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/133454-incidence-and-risk-factors-of-infections-among-diffuse-large-b-cell-lymphoma-and-classical-hodgkins-lymphoma-patients-in-a-tertiary-care-center-in-saudi-arabia-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:51:56Z","timestamp":1707508316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/133454-incidence-and-risk-factors-of-infections-among-diffuse-large-b-cell-lymphoma-and-classical-hodgkins-lymphoma-patients-in-a-tertiary-care-center-in-saudi-arabia-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.35922","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}